Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKT Alkami Technology	$25.69 +1.7%	$26.28	$19.94 ▼ $42.29	$2.63B	0.57	2.01 million shs	918,436 shs
APDN Applied DNA Sciences	$3.19 -1.8%	$4.54	$3.12 ▼ $1,976.25	$4.20M	-0.02	76,718 shs	49,352 shs
DY Dycom Industries	$256.76 +0.4%	$257.86	$131.37 ▼ $285.64	$7.40B	1.34	456,618 shs	340,820 shs
GDYN Grid Dynamics	$8.07	$9.86	$7.46 ▼ $25.50	$683.29M	1.06	1.61 million shs	1.42 million shs
IOVA Iovance Biotherapeutics	$2.23 -7.9%	$2.33	$1.64 ▼ $12.51	$875.69M	0.88	15.49 million shs	10.99 million shs
NVAX Novavax	$7.58	$7.38	$5.01 ▼ $15.22	$1.23B	2.5	9.32 million shs	6.38 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKT Alkami Technology	+1.98%	+13.37%	-10.33%	-11.89%	-24.11%
APDN Applied DNA Sciences	-2.99%	+0.93%	-34.87%	-33.62%	-99.82%
DY Dycom Industries	-0.40%	-0.74%	-3.13%	+11.97%	+48.30%
GDYN Grid Dynamics	+0.88%	+4.81%	-21.80%	-36.46%	-40.35%
IOVA Iovance Biotherapeutics	-1.22%	-4.35%	-17.97%	+32.24%	-78.77%
NVAX Novavax	+1.07%	-13.27%	+4.12%	+5.42%	-32.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKT Alkami Technology	3.2312 of 5 stars	3.4	2.0	0.0	4.1	3.3	0.6
APDN Applied DNA Sciences	0.4429 of 5 stars	0.0	2.0	0.0	3.3	0.0	0.6
DY Dycom Industries	4.4603 of 5 stars	3.5	5.0	2.6	2.6	1.7	1.3
GDYN Grid Dynamics	3.1254 of 5 stars	3.5	2.0	0.0	4.1	2.5	0.6
IOVA Iovance Biotherapeutics	4.6039 of 5 stars	4.2	4.0	4.2	1.6	2.5	0.6
NVAX Novavax	4.5408 of 5 stars	3.1	2.0	4.7	2.5	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKT Alkami Technology	2.75	Moderate Buy	$39.25	52.78% Upside
APDN Applied DNA Sciences	0.00	N/A	N/A	N/A
DY Dycom Industries	3.00	Buy	$289.43	12.72% Upside
GDYN Grid Dynamics	3.00	Buy	$15.75	95.17% Upside
IOVA Iovance Biotherapeutics	2.36	Hold	$11.90	433.63% Upside
NVAX Novavax	2.13	Hold	$14.29	88.47% Upside

Current Analyst Ratings Breakdown

Latest IOVA, APDN, ALKT, GDYN, NVAX, and DY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	NVAX Novavax	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/21/2025	DY Dycom Industries	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$290.00 ➝ $300.00
8/21/2025	DY Dycom Industries	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$265.00 ➝ $300.00
8/21/2025	DY Dycom Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$250.00 ➝ $275.00
8/21/2025	DY Dycom Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$288.00 ➝ $296.00
8/20/2025	GDYN Grid Dynamics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$13.00 ➝ $11.00
8/20/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform	$9.00 ➝ $7.00
8/19/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/18/2025	DY Dycom Industries	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$250.00 ➝ $295.00
8/12/2025	IOVA Iovance Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	DY Dycom Industries	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKT Alkami Technology	$333.85M	8.01	N/A	N/A	$3.31 per share	7.76
APDN Applied DNA Sciences	$3.43M	1.20	N/A	N/A	$5.41 per share	0.59
DY Dycom Industries	$4.70B	1.58	$15.12 per share	16.98	$47.31 per share	5.43
GDYN Grid Dynamics	$350.57M	1.95	$0.35 per share	23.29	$6.29 per share	1.28
IOVA Iovance Biotherapeutics	$164.07M	4.92	N/A	N/A	$1.93 per share	1.16
NVAX Novavax	$682.16M	1.80	N/A	N/A	$0.23 per share	32.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKT Alkami Technology	-$40.83M	-$0.38	N/A	N/A	N/A	-9.99%	-5.81%	-3.14%	10/29/2025 (Estimated)
APDN Applied DNA Sciences	-$6.99M	-$923.81	N/A	∞	N/A	-399.91%	-136.17%	-101.95%	N/A
DY Dycom Industries	$233.41M	$8.90	28.85	31.82	1.24	5.23%	21.17%	8.73%	N/A
GDYN Grid Dynamics	$4.04M	$0.19	42.48	∞	N/A	4.37%	1.89%	1.64%	10/30/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.23	N/A	N/A	N/A	-161.44%	-52.87%	-41.31%	11/6/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.28	3.32	94.75	0.10	39.20%	-142.33%	28.65%	11/11/2025 (Estimated)

Latest IOVA, APDN, ALKT, GDYN, NVAX, and DY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2026	DY Dycom Industries	$2.92	$3.33	+$0.41	$3.33	$1.41 billion	$1.38 billion
8/14/2025	Q3 2025	APDN Applied DNA Sciences	-$37.50	-$34.00	+$3.50	-$34.00	$1.28 million	$0.30 million
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million
8/6/2025	Q2 2025	NVAX Novavax	-$0.07	$0.62	+$0.69	$0.62	$149.19 million	$239.24 million
7/31/2025	Q2 2025	GDYN Grid Dynamics	$0.10	$0.10	N/A	$0.06	$100.45 million	$101.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKT Alkami Technology	N/A	N/A	N/A	N/A	N/A
APDN Applied DNA Sciences	N/A	N/A	N/A	N/A	N/A
DY Dycom Industries	N/A	N/A	N/A	N/A	N/A
GDYN Grid Dynamics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKT Alkami Technology	1.17	2.68	2.68
APDN Applied DNA Sciences	N/A	2.76	2.60
DY Dycom Industries	0.74	3.16	2.96
GDYN Grid Dynamics	N/A	7.37	7.37
IOVA Iovance Biotherapeutics	N/A	3.27	2.89
NVAX Novavax	5.93	2.36	2.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKT Alkami Technology	54.97%
APDN Applied DNA Sciences	22.22%
DY Dycom Industries	98.33%
GDYN Grid Dynamics	71.18%
IOVA Iovance Biotherapeutics	77.03%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
ALKT Alkami Technology	18.10%
APDN Applied DNA Sciences	0.03%
DY Dycom Industries	3.72%
GDYN Grid Dynamics	7.20%
IOVA Iovance Biotherapeutics	10.30%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKT Alkami Technology	850	104.08 million	85.24 million	Optionable
APDN Applied DNA Sciences	70	1.29 million	1.29 million	Optionable
DY Dycom Industries	15,623	28.95 million	27.88 million	Optionable
GDYN Grid Dynamics	4,730	84.67 million	78.57 million	Optionable
IOVA Iovance Biotherapeutics	500	361.85 million	324.58 million	Optionable
NVAX Novavax	1,990	162.42 million	160.80 million	Optionable

IOVA, APDN, ALKT, GDYN, NVAX, and DY Headlines

Recent News About These Companies

Robert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk Groups

August 28 at 3:09 PM | msn.com

Novavax (NVAX) Is Up After FDA Approves Updated Nuvaxovid for Key High-Risk Groups—What's Changed

August 28 at 3:09 PM | finance.yahoo.com

FDA Approves Updated COVID-19 Vaccines but With Restrictions

August 28 at 1:06 PM | zacks.com

Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term

August 28 at 10:50 AM | zacks.com

Novavax, Inc. (NVAX) Launches Protein-Based Vaccine for High-Risk Adults

August 28 at 6:31 AM | insidermonkey.com

511,742 Shares in Novavax, Inc. $NVAX Purchased by Jump Financial LLC

August 28 at 6:15 AM | marketbeat.com

RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines

August 27 at 3:30 PM | benzinga.com

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

August 27 at 3:07 PM | prnewswire.com

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

August 27 at 10:00 AM | zacks.com

Novavax, Inc. $NVAX Shares Sold by Vanguard Group Inc.

August 25 at 3:14 AM | marketbeat.com

Novavax (NVAX): How Debt Extension and Fresh Funding Shape Its Current Valuation

August 24, 2025 | finance.yahoo.com

Notable healthcare headlines for the week: Novo Nordisk, Medtronic, Novavax in focus

August 24, 2025 | seekingalpha.com

Novavax Faces Stock Slump Amid Downgrade

August 23, 2025 | tipranks.com

Novavax Shares Are Trading Higher Thursday: What's Going On?

August 22, 2025 | benzinga.com

What the Options Market Tells Us About Novavax

August 22, 2025 | benzinga.com

Bank of America Reiterates Underperform Rating for Novavax (NASDAQ:NVAX)

August 22, 2025 | marketbeat.com

Novavax Announces $225M Convertible Senior Notes Issuance

August 21, 2025 | tipranks.com

Novavax announces convertible debt refinancing

August 21, 2025 | seekingalpha.com

Novavax Announces Convertible Debt Refinancing

August 21, 2025 | prnewswire.com

Fox Run Management L.L.C. Invests $479,000 in Novavax, Inc. $NVAX

August 21, 2025 | marketbeat.com

B of A Securities Downgrades Novavax (NVAX)

August 20, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IOVA, APDN, ALKT, GDYN, NVAX, and DY Company Descriptions

Alkami Technology NASDAQ:ALKT

$25.69 +0.42 (+1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$25.68 -0.01 (-0.04%)

As of 05:26 PM Eastern

Alkami Technology, Inc. offers cloud-based digital banking solutions in the United States. The company's Alkami Platform allows financial institutions to onboard and engage new users, accelerate revenues, and enhance operational efficiency, with the support of a proprietary, cloud-based, and multi-tenant architecture. It serves community, regional, super-regional credit unions, and banks. The company was founded in 2009 and is headquartered in Plano, Texas.

Applied DNA Sciences NASDAQ:APDN

$3.19 -0.06 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 -0.02 (-0.47%)

As of 07:55 PM Eastern

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Dycom Industries NYSE:DY

$256.76 +1.13 (+0.44%)

Closing price 03:59 PM Eastern

Extended Trading

$255.60 -1.17 (-0.46%)

As of 07:50 PM Eastern

Dycom Industries, Inc. provides specialty contracting services to the telecommunications infrastructure and utility industries in the United States. The company offers engineering services to telecommunications providers, including the planning and design of aerial, underground, and buried fiber optic, copper, and coaxial cable systems; wireless networks in connection with the deployment of macro cell and new small cell sites; and program and project management and inspection personnel. It also provides construction, maintenance, and installation services for telephone companies and cable multiple system operators, such as placement and splicing of copper, fiber, and coaxial cables; tower construction, lines and antenna installation, foundation and equipment pad construction, and small cell site placement for wireless carriers, as well as equipment installation and material fabrication, and site testing services; underground facility locating services comprising locating telephone, cable television, power, water, sewer, and gas lines; installation and maintenance of customer premise equipment, including digital video recorders, set top boxes, and modems for cable system operators; and construction and maintenance services for electric and gas utilities, and other customers. Dycom Industries, Inc. was incorporated in 1969 and is headquartered in Palm Beach Gardens, Florida.

Grid Dynamics NASDAQ:GDYN

$8.07 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$8.10 +0.04 (+0.43%)

As of 04:46 PM Eastern

Grid Dynamics Holdings, Inc., together with its subsidiaries, provides technology consulting, platform and product engineering, and analytics services in North America, Europe, and internationally. It offers cloud platform and product engineering services, such as architecting, designing, and building scalable and secure cloud-based platforms and business applications; and AI/machine learning and data platform engineering services that build platforms to facilitate batch and streaming data ingestion, quality governance, orchestration, semantic modeling, observability, and analysis at scale. The company provides digital engagement services, including digital ecosystem design and implementation; and supply chain, Internet of Thing, and advanced manufacturing, which focuses on transforming traditional operations into smart and connected ecosystems. It serves customers that operate in the tech, media, telecommunications, retail, consumer packaged goods, manufacturing, and finance industries. The company was formerly known as ChaSerg Technology Acquisition Corp. and changed its name to Grid Dynamics Holdings, Inc. Grid Dynamics Holdings, Inc. was founded in 2006 and is headquartered in San Ramon, California.

Iovance Biotherapeutics NASDAQ:IOVA

$2.23 -0.19 (-7.85%)

Closing price 04:00 PM Eastern

Extended Trading

$2.20 -0.02 (-1.12%)

As of 07:57 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Novavax NASDAQ:NVAX

$7.58 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.56 -0.03 (-0.33%)

As of 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IOVA, APDN, ALKT, GDYN, NVAX, and DY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IOVA, APDN, ALKT, GDYN, NVAX, and DY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IOVA, APDN, ALKT, GDYN, NVAX, and DY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IOVA, APDN, ALKT, GDYN, NVAX, and DY Company Descriptions

Alkami Technology NASDAQ:ALKT

Applied DNA Sciences NASDAQ:APDN

Dycom Industries NYSE:DY

Grid Dynamics NASDAQ:GDYN

Iovance Biotherapeutics NASDAQ:IOVA

Novavax NASDAQ:NVAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools